Molecular Partners Ag (MOLN) Research & Development (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Research & Development of -$12061.3 for Q1 2026, up 9.03% year-over-year from -$11062.0 in Q1 2025, and down 100.02% quarter-over-quarter from $50.3 million in Q4 2025.
Molecular Partners Ag (MOLN) Research & Development (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Research & Development for 7 consecutive years, with -$12061.3 the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 9.03% year-over-year to -$12061.3; the TTM figure through Mar 2026 stood at $50.3 million (down 9.36% YoY), while the FY2025 annual figure was $50.3 million, down 9.36% from the prior year.
- Research & Development eased to -$12061.3 in Q1 2026 per MOLN's latest filing, from $50.3 million in the prior quarter.
- Across five years, Research & Development topped out at $55.5 million in Q4 2024 and bottomed at -$13.1 million in Q2 2022.
- Historically, Research & Development has averaged $11.0 million across 5 years, with a median of -$12539.3 in 2024.
- Annual changes were most pronounced in 2023 — Research & Development sank 187.59% — and 2024, when it surged 99.89%.
- Molecular Partners Ag's Research & Development stood at $52.7 million in 2022, then advanced by 4.4% to $55.0 million in 2023, then advanced by 0.89% to $55.5 million in 2024, then dropped by 9.36% to $50.3 million in 2025, then slumped by 100.02% to -$12061.3 in 2026.
- Business Quant data shows MOLN's Research & Development at -$12061.3 in Q1 2026, $50.3 million in Q4 2025, and -$10410.9 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | -12,061.31 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12,061.31 |
| Dec 31, 2025 | 50.33 Mn |
| Sep 30, 2025 | -10,410.91 |
| Jun 30, 2025 | -12,931.67 |
| Mar 31, 2025 | -13,259.14 |
| Dec 31, 2024 | 55.53 Mn |
| Sep 30, 2024 | -12,539.31 |
| Jun 30, 2024 | -14,471.52 |
| Mar 31, 2024 | -16,158.70 |
| Dec 31, 2023 | 55.04 Mn |
| Sep 30, 2023 | -13,140.89 |
| Jun 30, 2023 | -12.94 Mn |
| Mar 31, 2023 | -13,725.36 |
| Dec 31, 2022 | 52.72 Mn |
| Sep 30, 2022 | -11,903.61 |
| Jun 30, 2022 | -13.05 Mn |
| Mar 31, 2022 | 15,670.40 |
| Dec 31, 2021 | 60.47 Mn |
| Sep 30, 2021 | -12,723.21 |
| Jun 30, 2021 | -34.65 Mn |